Form 4: CFO Griffith Exits SONN Shares Post-Merger

Sonnet BioTherapeutics CFO Donald J. Griffith reported the disposition of all 10,375 common shares following the company's merger into Hyperliquid Strategies Inc.

Summary

• Donald J. Griffith, Chief Financial Officer and Director of Sonnet BioTherapeutics Holdings, Inc., reported the disposition of 10,375 shares of common stock.
• This transaction occurred on December 2, 2025, as a direct result of a Business Combination Agreement (BCA) dated July 11, 2025.
• Under the BCA, Sonnet BioTherapeutics Holdings, Inc. merged with and into Company Merger Sub, with Sonnet surviving as a direct wholly-owned subsidiary of Hyperliquid Strategies Inc (HSI).
• The 10,375 shares comprised 10,000 restricted stock units (RSUs) granted on July 11, 2025, which vested at the effective time of the merger, and 375 previously vested RSUs.
• Each restricted stock unit was exchanged for one-fifth of a share of HSI Common Stock and one Contingent Value Right (CVR).
• Following this transaction, Mr. Griffith holds 0 shares of Sonnet BioTherapeutics Holdings, Inc.
• All reported amounts reflect the company's 1:22 reverse stock split effective August 31, 2023, and a 1:8 reverse stock split effective September 30, 2024.

Sentiment

Score: 7

Explanation: The filing reports a standard transaction following a merger, indicating the successful completion of a corporate action. For the reporting person, it represents the conversion of their equity into the acquiring entity's stock and CVRs, which is a positive outcome for their compensation. The disposition of shares in the acquired entity is a neutral, expected event in this context.

Positives

• The reporting person successfully converted their equity in Sonnet BioTherapeutics Holdings, Inc. into shares of Hyperliquid Strategies Inc (HSI) Common Stock and Contingent Value Rights (CVRs) as part of the merger, indicating a successful completion of the corporate action for their compensation.

Negatives

• The reporting person no longer holds any direct beneficial ownership in Sonnet BioTherapeutics Holdings, Inc. common stock, as the company became a wholly-owned subsidiary of HSI.

Future Outlook

NA

Industry Context

This filing reflects the finalization of a corporate merger, a common strategic move in the biotechnology sector for companies seeking to combine assets, technologies, or market reach, or for smaller entities to be acquired by larger ones. The exchange of equity for shares in the acquiring entity and Contingent Value Rights (CVRs) is a standard mechanism in such transactions.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of executive compensation is a standard practice across industries, including biotechnology, aligning executive incentives with company performance.
• The exchange of shares in an acquired company for shares in the acquiring entity, often with a fractional share component or contingent value rights (CVRs), is a common structure in M&A transactions, particularly in biotech where future milestones or clinical trial outcomes can significantly impact value. For example, similar structures have been seen in acquisitions like Celgene by Bristol-Myers Squibb, where CVRs were used to tie additional payments to regulatory approvals of specific drugs.
• Reverse stock splits are frequently employed by companies, especially in the biotech sector, to increase share price and meet listing requirements or improve market perception, as seen with many small-cap biotechs prior to significant corporate actions.

Stakeholder Impact

• Shareholders (of Sonnet BioTherapeutics): Their shares would have been exchanged for HSI shares and CVRs as part of the merger, similar to the reporting person's RSUs. This filing confirms the completion of the merger and the conversion of equity.
• Employees (of Sonnet BioTherapeutics): The merger likely impacts employees, potentially through integration into HSI or changes in roles, though this filing specifically addresses executive equity.

Key Dates

Recommendation

This Form 4 filing details an insider's disposition of shares in Sonnet BioTherapeutics Holdings, Inc. following its merger into Hyperliquid Strategies Inc. The transaction is a procedural outcome of a corporate action (merger) and does not provide new information about the operational or financial performance of either company. For investors, the focus should shift to Hyperliquid Strategies Inc. and its future prospects, as Sonnet BioTherapeutics is now a wholly-owned subsidiary. The filing itself does not offer a basis for a 'buy' or 'sell' recommendation on Sonnet BioTherapeutics, as its independent trading existence has effectively ceased. A 'hold' recommendation reflects the neutral nature of this specific reporting event, with the understanding that any investment decision would now pertain to HSI.

Keywords

Sonnet BioTherapeutics, SONN, Donald J. Griffith, Hyperliquid Strategies Inc, HSI, Merger, Form 4, Insider Trading, Restricted Stock Units, RSU, Contingent Value Rights, CVR, Business Combination Agreement, CFO, Director